Literature DB >> 20367695

Comparative effectiveness research: evidence-based medicine meets health care reform in the USA.

Sandra J Tanenbaum1.   

Abstract

Rationale Comparative effectiveness research (CER) is the study of two or more approaches to a health problem to determine which one results in better health outcomes. It is viewed by some in the USA as a promising strategy for health care reform. Aims and Objectives In this paper, nascent US CER policy will be described and analysed in order to determine its similarities and differences with EBM and its chances of success. Methods Document review and process tracing Results CER shares the logic of policies promoting evidence-based medicine, but invites greater methodological flexibility to ensure external validity across a range of health care topics. Conclusions This may narrow the inferential distance from knowledge to action, but efforts to change the US health care system through CER will face familiar epistemological quandaries and 'patient-centred' politics on the left and right.

Entities:  

Mesh:

Year:  2009        PMID: 20367695     DOI: 10.1111/j.1365-2753.2009.01322.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  4 in total

Review 1.  Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research.

Authors:  Naihua Duan; Richard L Kravitz; Christopher H Schmid
Journal:  J Clin Epidemiol       Date:  2013-08       Impact factor: 6.437

2.  Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.

Authors:  Fang Liz Zhou; Fen Ye; Paulos Berhanu; Vineet E Gupta; Rishab A Gupta; Jennifer Sung; Jukka Westerbacka; Timothy S Bailey; Lawrence Blonde
Journal:  Diabetes Obes Metab       Date:  2018-01-24       Impact factor: 6.577

3.  Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.

Authors:  Timothy S Bailey; Fang L Zhou; Rishab A Gupta; Ronald Preblick; Vineet E Gupta; Paulos Berhanu; Lawrence Blonde
Journal:  Diabetes Obes Metab       Date:  2019-04-05       Impact factor: 6.577

4.  Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.

Authors:  Sean D Sullivan; Timothy S Bailey; Ronan Roussel; Fang Liz Zhou; Zsolt Bosnyak; Ronald Preblick; Jukka Westerbacka; Rishab A Gupta; Lawrence Blonde
Journal:  Diabetes Obes Metab       Date:  2018-06-25       Impact factor: 6.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.